- « Previous
- Clinical Pharmacology
- Next »
Lamictal
Clinical Pharmacology
Clinical Pharmacology
Lamictal
The pharmacokinetics of lamotrigine have been studied in patients with epilepsy, healthy young and elderly volunteers, and volunteers with chronic renal failure. Lamotrigine pharmacokinetic parameters for adult and pediatric patients and healthy normal volunteers are summarized in Tables 1 and 2.
Table 1. Mean* Pharmacokinetic Parameters in Healthy Volunteers
and Adult Patients
With Epilepsy
| Adult Study Population | Number of Subjects |
Tmax: Time of Maximum Plasma Concentration (h) |
t½: Elimination Half-life (h) |
Cl/F: Apparent Plasma Clearance (mL/min/kg) |
| Healthy volunteers taking no other medications: | ||||
| Single-dose LAMICTAL | 179 | 2.2 (0.25-12.0) |
32.8 (14.0-103.0) |
0.44 (0.12-1.10) |
| Multiple-dose LAMICTAL | 36 | 1.7 (0.5-4.0) |
25.4 (11.6-61.6) |
0.58 (0.24-1.15) |
| Healthy volunteers taking valproate: | ||||
| Single-dose LAMICTAL | 6 | 1.8 (1.0-4.0) |
48.3 (31.5-88.6) |
0.30 (0.14-0.42) |
| Multiple-dose LAMICTAL | 18 | 1.9 (0.5-3.5) |
70.3 (41.9-113.5) |
0.18 (0.12-0.33) |
| Patients with epilepsy taking valproate only: | ||||
| Single-dose LAMICTAL Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone† plus valproate: |
4 | 4.8 (1.8-8.4) |
58.8 (30.5-88.8) |
0.28 (0.16-0.40) |
| Single-dose LAMICTAL Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone† : |
25 | 3.8 (1.0-10.0) |
27.2 (11.2-51.6) |
0.53 (0.27-1.04) |
| Single-dose LAMICTAL | 24 | 2.3 (0.5-5.0) |
14.4 (6.4-30.4) |
1.10 (0.51-2.22) |
| Multiple-dose LAMICTAL | 17 | 2.0 (0.75-5.93) |
12.6 (7.5-23.1) |
1.21 (0.66-1.82) |
| * The majority of parameter means determined
in each study had coefficients of variation between 20% and 40% for half-life
and Cl/F and between 30% and 70% for Tmax. The overall mean values were
calculated from individual study means that were weighted based on the
number of volunteers/patients in each study. The numbers in parentheses
below each parameter mean represent the range of individual volunteer/patient
values across studies. † Carbamazepine, phenobarbital, phenytoin, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives and rifampin have also been shown to increase the apparent clearance of lamotrigine (see CLINICAL PHARMACOLOGY: Drug Interactions and PRECAUTIONS: DRUG INTERACTIONS). |
||||
Absorption
Brand Name: Lamictal
Generic Name: Lamotrigine
Generic Name: Lamotrigine
- « Previous
- Clinical Pharmacology
- Next »
Brain Surgery in Epileptics
A new method for treating children with epilepsy involves pinpoint mapping of the brain and removing those epileptic seizure points. See more WebMD Videos »
Epilepsy
Find tips and treatments to control seizures.
